FLT3 and acute myeloid leukemia: Decitabine and midostaurin have been combined in a phase I study in patients with relapsed/refractory AML with or without FLT3 mutations based on in vitro evidence of synergy against FLT3-internal tandem duplication (FLT3-ITD+) cells [33].